Editas Medicine to Host Strategic Update Webinar to Detail Progress Towards 2024 Goals, Including Achievement of Establishing In Vivo Preclinical Proof of Concept
Rhea-AI Summary
Editas Medicine (Nasdaq: EDIT), a clinical-stage gene editing company, has announced a strategic update webinar scheduled for Tuesday, October 22, 2024, at 8:00 a.m. ET. The webinar will focus on the company's progress towards its 2024 goals, including the significant achievement of establishing in vivo preclinical proof of concept.
The presentation will also cover business development and financial updates. Interested parties can access the live and archived webcast through a provided link or via the Events & Presentations page on the company's website. A replay of the webinar will be available in the Investors section of the Editas Medicine website following the conclusion of the event.
This strategic update offers an opportunity for stakeholders to gain insights into Editas Medicine's recent advancements and future directions in the field of gene editing.
Positive
- None.
Negative
- None.
Webinar to be held on Tuesday, October 22, at 8:00 a.m. ET
CAMBRIDGE, Mass., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that it will host a Company-sponsored webinar on Tuesday, October 22, 2024, at 8:00 a.m. ET to share achievement of in vivo preclinical proof of concept data and business development and financial updates.
Webinar Presentation Details:
The live and archived webcast of the Company’s webinar presentation will be accessible through this webcast link, or through the Events & Presentations page of the “Investors” section of the Company’s website.
A replay of the webinar will be available upon conclusion of the webinar in the Investors section of the Editas Medicine website at https://www.editasmedicine.com/.
About Editas Medicine
As a clinical-stage gene editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas12a and CRISPR/Cas9 genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute’s Cas12a patent estate and Broad Institute and Harvard University’s Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visit www.editasmedicine.com.
FAQ
When is Editas Medicine (EDIT) hosting its strategic update webinar?
What key achievement will Editas Medicine (EDIT) discuss in the webinar?
How can investors access Editas Medicine's (EDIT) strategic update webinar?
What topics will be covered in Editas Medicine's (EDIT) October 2024 webinar?
Will there be a replay available for Editas Medicine's (EDIT) strategic update webinar?
